Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States

CONCLUSIONS: In this real-world study, similar treatment persistence, dose escalation, and rates of opportunistic or serious infections were observed with VDZ- and UST-treated patients with CD. However, VDZ was associated with a significantly lower cost outlay for healthcare systems.PMID:38586979 | DOI:10.1080/03007995.2024.2326585

Source: Current Medical Research and Opinion - April 8, 2024 Category: Research Authors: Michael Chiorean Jeanne Jiang Ninfa Candela Grace Chen Hela Romdhani Dominick Latremouille-Viau Sherry Shi Rebecca Bungay Annie Guerin Tao Fan Source Type: research